Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 347


Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.

Højlund K, Glintborg D, Andersen NR, Birk JB, Treebak JT, Frøsig C, Beck-Nielsen H, Wojtaszewski JF.

Diabetes. 2008 Feb;57(2):357-66. Epub 2007 Oct 31.


Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.

Glintborg D, Hermann AP, Andersen M, Hagen C, Beck-Nielsen H, Veldhuis JD, Henriksen JE.

Fertil Steril. 2006 Aug;86(2):385-97. Epub 2006 Jun 16.


Soluble CD36 and risk markers of insulin resistance and atherosclerosis are elevated in polycystic ovary syndrome and significantly reduced during pioglitazone treatment.

Glintborg D, Højlund K, Andersen M, Henriksen JE, Beck-Nielsen H, Handberg A.

Diabetes Care. 2008 Feb;31(2):328-34. Epub 2007 Nov 13.


Impaired insulin activation and dephosphorylation of glycogen synthase in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.

Glintborg D, Højlund K, Andersen NR, Hansen BF, Beck-Nielsen H, Wojtaszewski JF.

J Clin Endocrinol Metab. 2008 Sep;93(9):3618-26. doi: 10.1210/jc.2008-0760. Epub 2008 Jun 10.


Inflammatory cytokines and chemokines, skeletal muscle and polycystic ovary syndrome: effects of pioglitazone and metformin treatment.

Ciaraldi TP, Aroda V, Mudaliar SR, Henry RR.

Metabolism. 2013 Nov;62(11):1587-96. doi: 10.1016/j.metabol.2013.07.004. Epub 2013 Aug 17.


Reduced expression of nuclear-encoded genes involved in mitochondrial oxidative metabolism in skeletal muscle of insulin-resistant women with polycystic ovary syndrome.

Skov V, Glintborg D, Knudsen S, Jensen T, Kruse TA, Tan Q, Brusgaard K, Beck-Nielsen H, Højlund K.

Diabetes. 2007 Sep;56(9):2349-55. Epub 2007 Jun 11.


Effects of endurance exercise training on insulin signaling in human skeletal muscle: interactions at the level of phosphatidylinositol 3-kinase, Akt, and AS160.

Frøsig C, Rose AJ, Treebak JT, Kiens B, Richter EA, Wojtaszewski JF.

Diabetes. 2007 Aug;56(8):2093-102. Epub 2007 May 18.


Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome.

Skov V, Glintborg D, Knudsen S, Tan Q, Jensen T, Kruse TA, Beck-Nielsen H, Højlund K.

PLoS One. 2008 Jun 18;3(6):e2466. doi: 10.1371/journal.pone.0002466.


Total and high molecular weight (HMW) adiponectin levels and measures of glucose and lipid metabolism following pioglitazone treatment in a randomized placebo-controlled study in polycystic ovary syndrome.

Glintborg D, Frystyk J, Højlund K, Andersen KK, Henriksen JE, Hermann AP, Hagen C, Flyvbjerg A, Andersen M.

Clin Endocrinol (Oxf). 2008 Feb;68(2):165-74. Epub 2007 Sep 4.


Distinct signals regulate AS160 phosphorylation in response to insulin, AICAR, and contraction in mouse skeletal muscle.

Kramer HF, Witczak CA, Fujii N, Jessen N, Taylor EB, Arnolds DE, Sakamoto K, Hirshman MF, Goodyear LJ.

Diabetes. 2006 Jul;55(7):2067-76.


Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.

Berria R, Gastaldelli A, Lucidi S, Belfort R, De Filippis E, Easton C, Brytzki R, Cusi K, Jovanovic L, DeFronzo R.

Clin Pharmacol Ther. 2006 Aug;80(2):105-14. Epub 2006 Jun 30.


Plasma monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1alpha are increased in patients with polycystic ovary syndrome (PCOS) and associated with adiposity, but unaffected by pioglitazone treatment.

Glintborg D, Andersen M, Richelsen B, Bruun JM.

Clin Endocrinol (Oxf). 2009 Nov;71(5):652-8. doi: 10.1111/j.1365-2265.2009.03523.x. Epub 2009 Jan 19.


Rosiglitazone improves downstream insulin receptor signaling in type 2 diabetic patients.

Miyazaki Y, He H, Mandarino LJ, DeFronzo RA.

Diabetes. 2003 Aug;52(8):1943-50.


Intense electroacupuncture normalizes insulin sensitivity, increases muscle GLUT4 content, and improves lipid profile in a rat model of polycystic ovary syndrome.

Johansson J, Feng Y, Shao R, Lönn M, Billig H, Stener-Victorin E.

Am J Physiol Endocrinol Metab. 2010 Oct;299(4):E551-9. doi: 10.1152/ajpendo.00323.2010. Epub 2010 Jul 27.


Rab GTPase-activating protein AS160 is a major downstream effector of protein kinase B/Akt signaling in pancreatic beta-cells.

Bouzakri K, Ribaux P, Tomas A, Parnaud G, Rickenbach K, Halban PA.

Diabetes. 2008 May;57(5):1195-204. doi: 10.2337/db07-1469. Epub 2008 Feb 14.


Uncoupling protein 1 expression in murine skeletal muscle increases AMPK activation, glucose turnover, and insulin sensitivity in vivo.

Neschen S, Katterle Y, Richter J, Augustin R, Scherneck S, Mirhashemi F, Schürmann A, Joost HG, Klaus S.

Physiol Genomics. 2008 May 13;33(3):333-40. doi: 10.1152/physiolgenomics.00226.2007. Epub 2008 Mar 18.


Selective effects of pioglitazone on insulin and androgen abnormalities in normo- and hyperinsulinaemic obese patients with polycystic ovary syndrome.

Romualdi D, Guido M, Ciampelli M, Giuliani M, Leoni F, Perri C, Lanzone A.

Hum Reprod. 2003 Jun;18(6):1210-8.

Items per page

Supplemental Content

Write to the Help Desk